HER2-positive breast cancer has long been considered a clinically distinct disease, mainly because of the striking efficacy achieved by HER2-targeted treatments in the early and metastatic settings. However, the effectiveness of these therapies has been variable, and the development of different types of treatment resistance reveals the diversity of HER2-positive breast cancers. As part of efforts by the International Cancer Genome Consortium (ICGC) Breast Cancer Working Group, Ferrari and colleagues¹ established the gene expression profiles of HER2-positive breast tumours.

中文翻译：

---

HER2阳性乳腺癌治疗发展的新时代

长期以来，人们一直认为HER2阳性乳腺癌是一种临床上独特的疾病，这主要是由于在早期和转移性环境中以HER2为靶点的治疗所获得的惊人疗效。然而，这些疗法的有效性是可变的，并且不同类型的治疗抗性的发展揭示了HER2阳性乳腺癌的多样性。作为国际癌症基因组协会（ICGC）乳腺癌工作组努力的一部分，法拉利及其同事¹建立了HER2阳性乳腺肿瘤的基因表达谱。